|
1
|
Casali PG, Bielack S, Abecassis N, Aro HT,
Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan
B, et al: Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 29
(Suppl 4):iv79–iv95. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zoumpoulidou G, Alvarez-Mendoza C, Mancusi
C, Ahmed RM, Denman M, Steele CD, Tarabichi M, Roy E, Davies LR,
Manji J, et al: Therapeutic vulnerability to PARP1,2 inhibition in
RB1-mutant osteosarcoma. Nat Commun. 12:70642021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Whelan J, McTiernan A, Cooper N, Wong YK,
Francis M, Vernon S and Strauss SJ: Incidence and survival of
malignant bone sarcomas in England 1979–2007. Int J Cancer.
131:E508–E517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ta HT, Dass CR, Choong PFM and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He P, Xu S, Guo Z, Yuan P, Liu Y, Chen Y,
Zhang T, Que Y and Hu Y: Pharmacodynamics and pharmacokinetics of
PLGA-based doxorubicin-loaded implants for tumor therapy. Drug
Deliv. 29:478–488. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Whelan JS and Davis LE: Osteosarcoma,
chondrosarcoma, and chordoma. J Clin Oncol. 36:188–193. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lagmay JP, Krailo MD, Dang H, Kim A,
Hawkins DS, Beaty O III, Widemann BC, Zwerdling T, Bomgaars L,
Langevin AM, et al: Outcome of patients with recurrent osteosarcoma
enrolled in seven phase II trials through children's cancer group,
pediatric oncology group, and children's oncology group: learning
from the past to move forward. J Clin Oncol. 34:3031–3038. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Link MP, Goorin AM, Miser AW, Green AA,
Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick
JA, et al: The effect of adjuvant chemotherapy on relapse-free
survival in patients with osteosarcoma of the extremity. N Engl J
Med. 314:1600–1606. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y: Cancer immunotherapy: Harnessing
the immune system to battle cancer. J Clin Invest. 125:3335–3337.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gattinoni L, Powell DJ Jr, Rosenberg SA
and Restifo NP: Adoptive immunotherapy for cancer: Building on
success. Nat Rev Immunol. 6:383–393. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shionoya Y, Kanaseki T, Miyamoto S, Tokita
S, Hongo A, Kikuchi Y, Kochin V, Watanabe K, Horibe R, Saijo H, et
al: Loss of tapasin in human lung and colon cancer cells and escape
from tumor-associated antigen-specific CTL recognition.
Oncoimmunology. 6:e12744762017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toor SM and Elkord E: Therapeutic
prospects of targeting myeloid-derived suppressor cells and immune
checkpoints in cancer. Immunol Cell Biol. 96:888–897. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
international TILs working group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mantovani A and Sica A: Macrophages,
innate immunity and cancer: Balance, tolerance, and diversity. Curr
Opin Immunol. 22:231–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fridman WH, Pagès F, Sautès-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rodell CB, Arlauckas SP, Cuccarese MF,
Garris CS, Li R, Ahmed MS, Kohler RH, Pittet MJ and Weissleder R:
TLR7/8-agonist-loaded nanoparticles promote the polarization of
tumour-associated macrophages to enhance cancer immunotherapy. Nat
Biomed Eng. 2:578–588. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Phanstiel DH, Van Bortle K, Spacek D, Hess
GT, Shamim MS, Machol I, Love MI, Aiden EL, Bassik MC and Snyder
MP: Static and dynamic DNA loops form AP-1-bound activation hubs
during macrophage development. Mol Cell. 67:1037–1048.e6. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Demaria O, Cornen S, Daëron M, Morel Y,
Medzhitov R and Vivier E: Publisher correction: Harnessing innate
immunity in cancer therapy. Nature. 576:E32019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chao MP, Weissman IL and Majeti R: The
CD47-SIRPα pathway in cancer immune evasion and potential
therapeutic implications. Curr Opin Immunol. 24:225–232. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu X, Pu Y, Cron K, Deng L, Kline J,
Frazier WA, Xu H, Peng H, Fu YX and Xu MM: CD47 blockade triggers T
cell-mediated destruction of immunogenic tumors. Nat Med.
21:1209–1215. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Advani R, Flinn I, Popplewell L, Forero A,
Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP,
et al: CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's
lymphoma. N Engl J Med. 379:1711–1721. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Munn DH and Bronte V: Immune suppressive
mechanisms in the tumor microenvironment. Curr Opin Immunol.
39:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Noy R and Pollard JW: Tumor-associated
macrophages: From mechanisms to therapy. Immunity. 41:49–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li
H, Wang J, Wen D, Zhang Y, Lu Y, et al: In situ sprayed
bioresponsive immunotherapeutic gel for post-surgical cancer
treatment. Nat Nanotechnol. 14:89–97. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Komohara Y, Fujiwara Y, Ohnishi K and
Takeya M: Tumor-associated macrophages: Potential therapeutic
targets for anti-cancer therapy. Adv Drug Deliv Rev. 99:180–185.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gordon S and Martinez FO: Alternative
activation of macrophages: Mechanism and functions. Immunity.
32:593–604. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang B, Zhao J, Li H, He KL, Chen Y, Chen
SH, Mayer L, Unkeless JC and Xiong H: Toll-like receptors on tumor
cells facilitate evasion of immune surveillance. Cancer Res.
65:5009–5014. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De Schutter T, Andrei G, Topalis D,
Duraffour S, Mitera T, van den Oord J, Matthys P and Snoeck R:
Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa
cells selected for resistance to cidofovir. Mol Cancer. 12:1582013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grauer OM, Molling JW, Bennink E, Toonen
LW, Sutmuller RP, Nierkens S and Adema GJ: TLR ligands in the local
treatment of established intracerebral murine gliomas. J Immunol.
181:6720–6729. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hagelueken G, Clarke BR, Huang H,
Tuukkanen A, Danciu I, Svergun DI, Hussain R, Liu H, Whitfield C
and Naismith JH: A coiled-coil domain acts as a molecular ruler to
regulate O-antigen chain length in lipopolysaccharide. Nat Struct
Mol Biol. 22:50–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wynn TA, Chawla A and Pollard JW:
Macrophage biology in development, homeostasis and disease. Nature.
496:445–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim J and Bae JS: Tumor-associated
macrophages and neutrophils in tumor microenvironment. Mediators
Inflamm. 2016:60581472016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH,
Wang XZ, Zhao YW and Wei YQ: Prognostic significance of
tumor-associated macrophages in solid tumor: A meta-analysis of the
literature. PLoS One. 7:e509462012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weilbaecher KN, Guise TA and McCauley LK:
Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
World Medical Association, . World medical
association declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sui C, Wu Y, Zhang R, Zhang T, Zhang Y, Xi
J, Ding Y, Wen J and Hu Y: Rutin inhibits the progression of
osteoarthritis through CBS-mediated RhoA/ROCK signaling. DNA Cell
Biol. 41:617–630. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He P, Hu Y, Huang C, Wang X, Zhang H,
Zhang X, Dai H, Wang R and Gao Y: N-butanol extract of gastrodia
elata suppresses inflammatory responses in
lipopolysaccharide-stimulated macrophages and complete freund's
adjuvant-(CFA-) induced arthritis rats via inhibition of MAPK
signaling pathway. Evid Based Complement Alternat Med.
2020:16586182020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gordon S: Alternative activation of
macrophages. Nat Rev Immunol. 3:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mohanty S, Aghighi M, Yerneni K, Theruvath
JL and Daldrup-Link HE: Improving the efficacy of osteosarcoma
therapy: Combining drugs that turn cancer cell ‘don't eat me’
signals off and ‘eat me’ signals on. Mol Oncol. 13:2049–2061. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feng M, Chen JY, Weissman-Tsukamoto R,
Volkmer JP, Ho PY, McKenna KM, Cheshier S, Zhang M, Guo N, Gip P,
et al: Macrophages eat cancer cells using their own calreticulin as
a guide: Roles of TLR and Btk. Proc Natl Acad Sci USA.
112:2145–2150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Singel KL and Segal BH: NOX2-dependent
regulation of inflammation. Clin Sci (Lond). 130:479–490. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tsuchiya H, Kanazawa Y, Abdel-Wanis ME,
Asada N, Abe S, Isu K, Sugita T and Tomita K: Effect of timing of
pulmonary metastases identification on prognosis of patients with
osteosarcoma: The Japanese musculoskeletal oncology group study. J
Clin Oncol. 20:3470–3477. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Palucka AK and Coussens LM: The basis of
oncoimmunology. Cell. 164:1233–1247. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Raval RR, Sharabi AB, Walker AJ, Drake CG
and Sharma P: Tumor immunology and cancer immunotherapy: Summary of
the 2013 SITC primer. J Immunother Cancer. 2:142014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jiang X, Wang J, Deng X, Xiong F, Ge J,
Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor
microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol
Cancer. 18:102019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Constantinidou A, Alifieris C and Trafalis
DT: Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): A
new era in cancer active immunotherapy. Pharmacol Ther. 194:84–106.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Quamine AE, Olsen MR, Cho MM and Capitini
CM: Approaches to enhance natural killer cell-based immunotherapy
for pediatric solid tumors. Cancers (Basel). 13:27962021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang RF and Wang HY: Immune targets and
neoantigens for cancer immunotherapy and precision medicine. Cell
Res. 27:11–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Callea M, Albiges L, Gupta M, Cheng SC,
Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, et al:
Differential expression of PD-L1 between primary and metastatic
sites in clear-cell renal cell carcinoma. Cancer Immunol Res.
3:1158–1164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Humphries MP, McQuaid S, Craig SG, Bingham
V, Maxwell P, Maurya M, McLean F, Sampson J, Higgins P, Greene C,
et al: Critical appraisal of programmed death ligand 1 reflex
diagnostic testing: Current standards and future opportunities. J
Thorac Oncol. 14:45–53. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shin DS, Zaretsky JM, Escuin-Ordinas H,
Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W,
Sandoval S, Torrejon DY, et al: Primary resistance to PD-1 blockade
mediated by JAK1/2 mutations. Cancer Discov. 7:188–201. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Syn NL, Teng MWL, Mok TSK and Soo RA:
De-novo and acquired resistance to immune checkpoint targeting.
Lancet Oncol. 18:e731–e741. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sau S, Petrovici A, Alsaab HO, Bhise K and
Iyer AK: PDL-1 antibody drug conjugate for selective chemo-guided
immune modulation of cancer. Cancers (Basel). 11:2322019.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Vonderheide RH: CD47 blockade as another
immune checkpoint therapy for cancer. Nat Med. 21:1122–1123. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Theruvath J, Menard M, Smith BAH, Linde
MH, Coles GL, Dalton GN, Wu W, Kiru L, Delaidelli A, Sotillo E, et
al: Anti-GD2 synergizes with CD47 blockade to mediate tumor
eradication. Nat Med. 28:333–344. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Willingham SB, Volkmer JP, Gentles AJ,
Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin
R, Cohen JD, et al: The CD47-signal regulatory protein alpha
(SIRPa) interaction is a therapeutic target for human solid tumors.
Proc Natl Acad Sci USA. 109:6662–6667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Perry CJ, Muñoz-Rojas AR, Meeth KM,
Kellman LN, Amezquita RA, Thakral D, Du VY, Wang JX, Damsky W,
Kuhlmann AL, et al: Myeloid-targeted immunotherapies act in synergy
to induce inflammation and antitumor immunity. J Exp Med.
215:877–893. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wiehagen KR, Girgis NM, Yamada DH, Smith
AA, Chan SR, Grewal IS, Quigley M and Verona RI: Combination of
CD40 agonism and CSF-1R blockade reconditions tumor-associated
macrophages and drives potent antitumor immunity. Cancer Immunol
Res. 5:1109–1121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mohanty S, Yerneni K, Theruvath JL, Graef
CM, Nejadnik H, Lenkov O, Pisani L, Rosenberg J, Mitra S, Cordero
AS, et al: Nanoparticle enhanced MRI can monitor macrophage
response to CD47 mAb immunotherapy in osteosarcoma. Cell Death Dis.
10:362019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Luo Z, Li P, Deng J, Gao N, Zhang Y, Pan
H, Liu L, Wang C, Cai L and Ma Y: Cationic polypeptide
micelle-based antigen delivery system: A simple and robust adjuvant
to improve vaccine efficacy. J Control Release. 170:259–267. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bocanegra Gondan AI, Ruiz-de-Angulo A,
Zabaleta A, Gómez Blanco N, Cobaleda-Siles BM, García-Granda MJ,
Padro D, Llop J, Arnaiz B, Gato M, et al: Effective cancer
immunotherapy in mice by polyIC-imiquimod complexes and engineered
magnetic nanoparticles. Biomaterials. 170:95–115. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Soto-Pantoja DR, Terabe M, Ghosh A,
Ridnour LA, DeGraff WG, Wink DA, Berzofsky JA and Roberts DD: CD47
in the tumor microenvironment limits cooperation between antitumor
T-cell immunity and radiotherapy. Cancer Res. 74:6771–6783. 2014.
View Article : Google Scholar : PubMed/NCBI
|
